
Cerenome reported $0.7 million in third-quarter diagnostic revenue as its CNSide business began submitting claims and receiving payments, while management outlined interim clinical results for its REYOBIQ cancer treatment and a potential path to positive contribution from diagnostics in late 2027.
The company expects to exit 2026 at an annualized rate of approximately 1,250 CNSide tests and $10 million to $12.5 million in gross billings, executives said on its third-quarter earnings call. Gross billings reflect list prices and are not the same as revenue or cash collected.
Chief Financial Officer Andrew Sims said Cerenome submitted claims for 222 tests with gross charges of approximately $1.55 million during the quarter. The company recognized $0.7 million in net diagnostic revenue, reflecting estimated contractual adjustments and price concessions, and collected about $0.1 million in cash in October.
Sims said Cerenome needs two to three quarters of billing and collections data before it can provide a forward revenue estimate. Payer reimbursement behavior and collection timing remain important variables.
Early REYOBIQ Data and Trial Plans
Chief Operating Officer Eric Daniels reviewed interim results from the first 10 patients in the ReSPECT-LM dose-optimization study of REYOBIQ for leptomeningeal metastasis, a cancer involving the tissue and fluid surrounding the brain and spinal cord. Patients had a mix of primary cancers, including breast, lung, melanoma and ovarian cancers.
Daniels said no dose-limiting toxicities had been observed and no patients had stopped treatment because of side effects. One patient received three doses totaling 79.2 millicuries, exceeding the 66-millicurie maximum feasible single dose identified in an earlier phase I study.
One patient experienced grade 3 treatment-related nausea that resolved in five days, while a serious adverse event involving shortness of breath was judged unrelated to the drug, Daniels said. He described the early disease-control findings as preliminary: One of the 10 patients had MRI-documented leptomeningeal progression through 7.5 months, three died of their primary cancer and six remained on study.
Formal efficacy measures are not yet assessable, Daniels said. The company is targeting enrollment of another 10 to 15 patients and expects a top-line readout in mid-2027 that will include measures of progression-free and overall survival, neurological function and quality of life.
Following the dose-optimization study, Cerenome plans to meet with the Food and Drug Administration to discuss a randomized phase II study. Chief Executive Officer Marc Hedrick said the company plans to start a randomized phase IIb study in the second half of 2027.
Cerenome also closed enrollment in its phase II ReSPECT-GBM trial for recurrent glioblastoma after treating 32 patients at the recommended dose, compared with an original plan of 34. Daniels said the company determined that stopping at 32 would have minimal impact on the power of the planned analysis. Top-line data are expected in mid-2027, with subsequent steps, including an FDA meeting, dependent on the results.
CNSide Adoption and Coverage
Russell Bradley, president and general manager of CNSide Diagnostics, said October testing volume was about 22% above the third-quarter monthly average. The company recorded 512 tumor cell enumeration tests year to date through October, with much of the volume occurring later in the year.
Twenty-six institutions and 45 providers are ordering the test, and another 34 institutions are in the onboarding queue, Bradley said. Nearly one in four patients has been tested more than once, including 23 who have been tested at least four times.
Cerenome launched a CNSide molecular profile test in October and plans to introduce breast cancer cellular protein expression assays in 2027. Bradley said the company now has approximately 190 million covered lives for its lead diagnostic assay and expects Medicare reimbursement in the first half of 2027.
The company is recruiting an initial four salespeople and expects them to be effective within 90 days of starting, Bradley said. Hedrick also announced that Samantha Fowlkes had joined as vice president of sales and that board member Ronnie Andrews had become chief business officer.
Loss Widens as Company Builds Commercial Team
Total third-quarter revenue fell to $0.7 million from $1.4 million a year earlier, when all revenue came from grants. The operating loss widened to $7.5 million from $4.5 million, while the net loss increased to $8.7 million, or $1.14 per share, from $4.4 million, or $1.03 per share.
Selling, general and administrative expense rose to $5.2 million from $3.4 million, largely because of higher compensation and recruiting costs as the company expanded its team, Sims said. Cerenome ended September with $4.9 million in cash equivalents and investments, then raised just under $4 million in October. Sims said access to a $20 million royalty and financing facility, if fully used, would extend the company’s runway into 2028.
Sims said testing, billing and collections could materially offset CNSide’s cash burn by the second half of 2027, with a potential positive contribution late in the year if current trends continue and the sales team is in place. During the question-and-answer session, he outlined a possible doubling of the gross billing run rate by year-end 2027, but Hedrick cautioned that the company was not yet ready to provide 2027 guidance.
About Plus Therapeutics (NASDAQ:PSTV)
Plus Therapeutics, Inc. is a clinical-stage biotechnology company developing targeted treatments and diagnostic tools for cancers affecting the central nervous system. Its work includes radiopharmaceutical therapies designed to deliver radiation to tumors while limiting exposure to surrounding healthy tissue. The company’s lead therapeutic program is Rhenium-186 NanoLiposome (RNL), an investigational treatment being studied for cancers including recurrent glioblastoma and leptomeningeal metastases.
